(CLABF) – Globe Newswire
-
Core One Labs’ Upgrades to OTCQB Venture Market
-
Core One Labs’ Akome Receives Positive Results from Bioassay Studies
-
Core One Labs to Investigate Soliciting Investment and Potential Takeover Opportunities
-
Core One’s Vocan Biotechnologies and Awakened Biosciences Collaborate to Advance Vocan’s Mass Production Capabilities
-
Core One Labs Proceeds with Next Milestone Achievement: To Produce Psilocybin
-
Core One Labs’ Akome Biotech Initiates Neurogenesis Stimulation and Modeling Studies: Advancing its Proprietary Psychedelic-based Pharmaceutical Formulations
-
Core One Labs Announces Successful Proof-of-Concept for Biosynthetic N-methyltryptamine (NMT)
-
Vancouver discovery will make ‘Magic Mushroom’ mental health care cheaper
-
Core One Labs’ Files Milestone Patent for Protection of its Recombinant Production System for Optimized Biosynthetic N-methyltryptamine (NMT)
-
Core One Labs Completes Strategic Acquisition of Awakened Biosciences and its Game-Changing Provisional Patents
-
Core One Labs Expects Imminent Breakthrough to Produce NMT, Precursor to DMT
-
Core One Labs’ Successful Patent Application Filing for Protection of its Biosynthetic Production System for Psilocybin Marks a Significant Milestone for the Progression of Psychedelic Health Care
-
Core One Labs’ Akome Biotech Signs Research Agreement with University of Barcelona, Faculty of Pharmacy and Food Sciences
-
Core One Labs Announces Successful Proof of Concept and Files Patent for Protection of its Recombinant Production System for Optimized Biosynthesis of Psilocybin
-
Core One Labs Special Investor Webcast Rescheduled to Friday, January 21, 2022
-
Core One Labs to Host Special Investor Webcast on Tuesday, January 18, 2022
-
Core One Labs Now Also Working to Biosynthesize DMT and Receives License
-
Core One Labs Applauds Health Canada’s Amendments to Special Access Program, Allowing Physicians to Request Patient Access to Psychedelic Treatments
-
Core One Labs Acquires New Path Laboratories
-
Core One Labs Applauds the City of Seattle in Their Efforts to Decriminalize Psylocibin and Other Natural Occuring Entheogenic Drugs
-
Core One Labs to Present on its Proprietary Biosynthetic Psilocybin Technology at Investor Town Hall Event on August 4, 2021
-
Core One Labs Announces Details of Consolidation to Meet Nasdaq Listing Requirements
-
REPEAT - New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
-
New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
-
Core One Labs Retains Canada’s Highest-Ranked IP Law Firm to Assist With Patent Filings
-
Core One Labs Plans Share Consolidation in Preparation of Listing its Common Shares on Nasdaq
-
REPEAT - Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent
-
Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent
-
REPEAT – Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer’s Disease
-
Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer’s Disease
-
REPEAT - World Renowned Physician Joins Core One Labs as Chief Medical Officer
-
World Renowned Physician Joins Core One Labs as Chief Medical Officer
-
REPEAT - Core One Labs Completes Milestone Acquisition of Akome Biotech
-
Core One Labs Completes Milestone Acquisition of Akome Biotech
-
REPEAT -- Core One Labs Reaches Definitive Agreement to Acquire Akome Biotech
-
Core One Labs Reaches Definitive Agreement to Acquire Akome Biotech
-
REPEAT -- Core One Labs to Explore Joint Venture with Lobe Sciences for the Clinical Development of Biosynthetic Psilocybin
-
Core One Labs to Explore Joint Venture with Lobe Sciences for the Clinical Development of Biosynthetic Psilocybin
-
Repeat: Core One Labs Vocan Biotechnologies Enters into Collaborative Research Agreement with UBC
-
Emerging Markets Report: The Rich Get Richer
-
Core One Labs Vocan Biotechnologies Enters into Collaborative Research Agreement with UBC
-
REPEAT: Core One Labs’ Vocan Initiates Engineering and Design of a Proprietary Production System for Manufacturing of API-Grade DMT
-
Core One Labs’ Vocan Initiates Engineering and Design of a Proprietary Production System for Manufacturing of API-Grade DMT
-
Emerging Markets Report: A Moment for the Mushroom
-
Core One Labs Files Application to List its Common Shares on NASDAQ
Back to CLABF Stock Lookup
